Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards, AtriCure, Boston Scientific, and Medtronic report strong earnings driven by TAVR, PFA, and cardiac ablation growth in 2025.

Edwards LifesciencesEW stock surged Friday after the medtech giant hiked its 2025 outlook following a key setback for rival Boston ScientificEW. In May, Boston Sci pulled its transcatheter aortic ...